« Return to News | Drug Sponsors | CROs/Service Providers

PPD and Merck in Strategic Outsourcing Deal

Tuesday, January 6, 2009 11:25 AM

Contract research organization (CRO) PPD has entered into a strategic collaboration with Merck that will significantly expand PPD’s global central laboratory business.

Under the terms of the agreement, PPD assumes control of Merck’s 130,000-square-foot vaccine testing laboratory and related equipment in Wayne, Pa., as well as 80 Merck employees who operate the facility.

PPD will provide a range of assay development and immunogenicity testing services as well as traditional central laboratory and sample storage services to Merck over the next five years.

“With this acquisition, we believe we are the first CRO to have a central lab that offers a comprehensive menu of assay development and testing services for vaccine clinical trials,” said Agostino Fede, senior vice president of PPD and head of global central labs, in a company release.

The PPD-Merck agreement is just the latest example of the growing trend toward strategic outsourcing agreements between CROs and big pharma. In August, Covance and Eli Lilly signed a $1.6-billion agreement to sell a major R&D facility to Covance. Lilly also cut smaller outsourcing agreements with Quintiles and i3 Statprobe in 2008.

PPD did not disclose financial details of the transaction. PPD’s shares were down 2.04% to $28.40 at end of day Monday.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.